Genentech priced avastin a lot lower than the market research stated they should. Based on the uptake, it appears they ahve done quite well (for patients and themselves). Who gives a shit what the wall st. journal thinks about it?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.